Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03443869




Registration number
NCT03443869
Ethics application status
Date submitted
19/02/2018
Date registered
23/02/2018
Date last updated
28/07/2023

Titles & IDs
Public title
Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)
Scientific title
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients
Secondary ID [1] 0 0
MK-8228-002
Secondary ID [2] 0 0
8228-002
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
CMV Disease 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Letermovir
Treatment: Drugs - Valganciclovir
Treatment: Drugs - Acyclovir (ACV)
Treatment: Drugs - Placebo to ACV
Treatment: Drugs - Placebo to LET
Treatment: Drugs - Placebo to VGCV

Experimental: Letermovir - LET 480mg (or 240 mg when administered concomitantly with cyclosporin A) tablet orally; placebo to VGCV tablet orally once daily; and 400 mg capsule of acyclovir (ACV) orally every 12 hours for 28 weeks

Active Comparator: Valganciclovir - 900 mg VGCV tablet orally, once daily; placebo to LET tablet orally once daily; and placebo to ACV orally every 12 hours for 28 weeks


Treatment: Drugs: Letermovir
LET 480mg (or 240 mg when administered concomitantly with cyclosporin A) once daily for 28 weeks

Treatment: Drugs: Valganciclovir
900 mg VGCV tablet orally, once daily for 28 weeks

Treatment: Drugs: Acyclovir (ACV)
400 mg over-encapsulated ACV tablet orally, every 12 hours for 28 weeks

Treatment: Drugs: Placebo to ACV
Over-encapsulated placebo tablet orally, every 12 hours for 28 weeks

Treatment: Drugs: Placebo to LET
Placebo to LET tablet orally, once daily for 28 weeks

Treatment: Drugs: Placebo to VGCV
Placebo to VGCV tablet orally, once daily for 28 weeks
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Adjudicated Cytomegalovirus (CMV) Disease Through 52 Weeks Post-transplant
Timepoint [1] 0 0
Up to 52 weeks
Secondary outcome [1] 0 0
Percentage of Participants With Adjudicated CMV Disease Through 28 Weeks Post-transplant
Timepoint [1] 0 0
Up to 28 weeks
Secondary outcome [2] 0 0
Time to Onset of Adjudicated CMV Disease Through 52 Weeks Post-transplant
Timepoint [2] 0 0
Up to 52 weeks
Secondary outcome [3] 0 0
Percentage of Participants With Any AE
Timepoint [3] 0 0
Up to 52 weeks
Secondary outcome [4] 0 0
Percentage of Participants With Any Drug-related Serious Adverse Event (SAE)
Timepoint [4] 0 0
Up to 52 weeks

Eligibility
Key inclusion criteria
- Have a documented negative serostatus for CMV within 180 days prior to randomization.

- Anticipate receiving a primary or secondary allograft kidney from a CMV IgG
seropositive (D+) donor at the time of screening AND have received a primary or
secondary allograft kidney from a documented D+ donor at the time of randomization.

- Be within 0 (i.e. day of transplantation) to 7 days (inclusive) post-kidney transplant
at the time of randomization.

- Males agree to use contraception during the treatment period, and for at least 90 days
after the last dose of study treatment, and refrain from donating sperm during this
period.

- Female is not pregnant, not breastfeeding, and is not a woman of childbearing
potential (WOCBP), OR if a WOCBP, agrees to follow the contraception guidance during
the treatment period and for at least 90 days after the last dose of study treatment.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Has received a previous solid organ transplant or hematopoietic stem cell transplant
(HSCT). Note: Participants who have received a prior primary allograft kidney may be
enrolled, provided that all other inclusion/exclusion criteria are met.

- Is a multi-organ transplant recipient (e.g. kidney-pancreas). Double kidney transplant
recipients (i.e. transplant of two kidneys from the same donor to the same recipient
simultaneously) will be excluded.

- Has a history of CMV disease or suspected CMV disease within 6 months prior to
randomization.

- Has suspected or known hypersensitivity to active or inactive ingredients of LET
formulations, VGCV, GCV, and/or ACV formulations.

- Is on dialysis or plasmapheresis at the time of randomization. Dialysis includes
hemofiltration.

- Has Child-Pugh Class C severe hepatic insufficiency at screening.

- Has both moderate hepatic insufficiency AND moderate-to-severe renal insufficiency at
screening.

- Has any uncontrolled infection on the day of randomization.

- Has documented positive results for human immunodeficiency virus antibody (HIV-Ab)
test at any time prior to randomization, or for hepatitis C virus antibody (HCV-Ab)
and with detectable HCV ribonucleic acid (RNA) within 90 days prior to randomization,
or hepatitis B surface antigen (HBsAg) within 90 days prior to randomization.

- Requires mechanical ventilation, or is hemodynamically unstable, at the time of
randomization.

- Has a history of malignancy =5 years prior to signing informed consent.

- Is pregnant or expecting to conceive, is breastfeeding, or plans to breastfeed from
the time of consent through at least 90 days following cessation of study therapy.

- Is expecting to donate eggs or sperm starting from the time of consent through at
least 90 days following cessation of study therapy.

- Has received within 30 days prior to randomization or plans to receive during the
study any of the following anti-CMV IgG antibody treatment or anti-CMV drug therapy
including the following: Cidofovir, CMV hyper-immune globulin, Any investigational CMV
antiviral agent/biologic therapy.

- Has received within 7 days prior to randomization or plans to receive during the study
any of the following anti-CMV drug therapy: LET, GCV, VGCV, Foscarnet, ACV,
Valacyclovir, Famciclovir.

- Is a user of recreational or illicit drugs or has had a recent history (within the
last year) of drug or alcohol abuse or dependence.

- Is currently participating or has participated in a study with an unapproved
investigational compound or device within 28 days, or 5× half-life of the
investigational compound whichever is longer, of initial dosing on this study.

- Has previously participated in this study or any other study involving LET.

- Has previously participated or is currently participating in any study involving
administration of a CMV vaccine or another CMV investigational agent, or is planning
to participate in a study of a CMV vaccine or another CMV investigational agent during
the course of this study.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
3/05/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
5/04/2022
Sample size
Target
Accrual to date
Final
601
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital ( Site 0005) - Camperdown
Recruitment hospital [2] 0 0
Westmead Hospital ( Site 0006) - Westmead
Recruitment hospital [3] 0 0
Princess Alexandra Hospital ( Site 0004) - Woolloongabba
Recruitment hospital [4] 0 0
Royal Adelaide Hospital ( Site 0003) - Adelaide
Recruitment hospital [5] 0 0
Monash Health-Monash Medical Centre ( Site 0008) - Clayton
Recruitment hospital [6] 0 0
Royal Melbourne Hospital ( Site 0007) - Parkville
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [4] 0 0
5000 - Adelaide
Recruitment postcode(s) [5] 0 0
3168 - Clayton
Recruitment postcode(s) [6] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Indiana
Country [6] 0 0
United States of America
State/province [6] 0 0
Louisiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Maryland
Country [8] 0 0
United States of America
State/province [8] 0 0
Massachusetts
Country [9] 0 0
United States of America
State/province [9] 0 0
Michigan
Country [10] 0 0
United States of America
State/province [10] 0 0
Nebraska
Country [11] 0 0
United States of America
State/province [11] 0 0
New Jersey
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Ohio
Country [15] 0 0
United States of America
State/province [15] 0 0
Pennsylvania
Country [16] 0 0
United States of America
State/province [16] 0 0
South Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Tennessee
Country [18] 0 0
United States of America
State/province [18] 0 0
Virginia
Country [19] 0 0
United States of America
State/province [19] 0 0
Washington
Country [20] 0 0
Argentina
State/province [20] 0 0
Buenos Aires
Country [21] 0 0
Argentina
State/province [21] 0 0
Caba
Country [22] 0 0
Argentina
State/province [22] 0 0
Corrientes
Country [23] 0 0
Argentina
State/province [23] 0 0
Santa Fe
Country [24] 0 0
Austria
State/province [24] 0 0
Tirol
Country [25] 0 0
Austria
State/province [25] 0 0
Wien
Country [26] 0 0
Belgium
State/province [26] 0 0
Antwerpen
Country [27] 0 0
Belgium
State/province [27] 0 0
Bruxelles-Capitale, Region De
Country [28] 0 0
Belgium
State/province [28] 0 0
Vlaams-Brabant
Country [29] 0 0
Canada
State/province [29] 0 0
Alberta
Country [30] 0 0
Canada
State/province [30] 0 0
British Columbia
Country [31] 0 0
Canada
State/province [31] 0 0
Ontario
Country [32] 0 0
Canada
State/province [32] 0 0
Quebec
Country [33] 0 0
Colombia
State/province [33] 0 0
Antioquia
Country [34] 0 0
Colombia
State/province [34] 0 0
Distrito Capital De Bogota
Country [35] 0 0
Colombia
State/province [35] 0 0
Santander
Country [36] 0 0
Colombia
State/province [36] 0 0
Valle Del Cauca
Country [37] 0 0
France
State/province [37] 0 0
Alpes-Maritimes
Country [38] 0 0
France
State/province [38] 0 0
Gironde
Country [39] 0 0
France
State/province [39] 0 0
Haute-Garonne
Country [40] 0 0
France
State/province [40] 0 0
Indre-et-Loire
Country [41] 0 0
France
State/province [41] 0 0
Val-de-Marne
Country [42] 0 0
France
State/province [42] 0 0
Paris
Country [43] 0 0
Germany
State/province [43] 0 0
Niedersachsen
Country [44] 0 0
Germany
State/province [44] 0 0
Nordrhein-Westfalen
Country [45] 0 0
Germany
State/province [45] 0 0
Berlin
Country [46] 0 0
Hungary
State/province [46] 0 0
Baranya
Country [47] 0 0
Hungary
State/province [47] 0 0
Csongrad
Country [48] 0 0
Hungary
State/province [48] 0 0
Budapest
Country [49] 0 0
Hungary
State/province [49] 0 0
Debrecen
Country [50] 0 0
Italy
State/province [50] 0 0
Piemonte
Country [51] 0 0
Italy
State/province [51] 0 0
Veneto
Country [52] 0 0
Italy
State/province [52] 0 0
Milano
Country [53] 0 0
Italy
State/province [53] 0 0
Roma
Country [54] 0 0
Mexico
State/province [54] 0 0
Morelos
Country [55] 0 0
Mexico
State/province [55] 0 0
Aguascalientes
Country [56] 0 0
Mexico
State/province [56] 0 0
Ciudad de Mexico
Country [57] 0 0
Mexico
State/province [57] 0 0
Mexico City
Country [58] 0 0
Mexico
State/province [58] 0 0
Veracruz
Country [59] 0 0
New Zealand
State/province [59] 0 0
Auckland
Country [60] 0 0
Poland
State/province [60] 0 0
Dolnoslaskie
Country [61] 0 0
Poland
State/province [61] 0 0
Mazowieckie
Country [62] 0 0
Poland
State/province [62] 0 0
Pomorskie
Country [63] 0 0
Poland
State/province [63] 0 0
Wielkopolskie
Country [64] 0 0
Poland
State/province [64] 0 0
Zachodniopomorskie
Country [65] 0 0
Spain
State/province [65] 0 0
La Coruna
Country [66] 0 0
Spain
State/province [66] 0 0
Barcelona
Country [67] 0 0
Spain
State/province [67] 0 0
Madrid
Country [68] 0 0
Spain
State/province [68] 0 0
Zaragoza
Country [69] 0 0
United Kingdom
State/province [69] 0 0
London, City Of
Country [70] 0 0
United Kingdom
State/province [70] 0 0
Birmingham

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Merck Sharp & Dohme LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary objective of this study is to evaluate the efficacy of letermovir (LET) versus
valganciclovir (VGCV) in preventing CMV disease in adult kidney transplant recipients. The
primary hypotheses are that LET is non-inferior to VGCV; and if non-inferiority is
demonstrated, that LET is superior to VGCV, in preventing CMV disease through 52 weeks
post-transplant.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03443869
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Merck Sharp & Dohme LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03443869